A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation.

  title={A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation.},
  author={A. W. Zuardi and J. Crippa and J. Hallak and S. Bhattacharyya and Z. Atakan and R. Martin-Santos and P. McGuire and F. Guimar{\~a}es},
  journal={Current pharmaceutical design},
  volume={18 32},
  • A. W. Zuardi, J. Crippa, +5 authors F. Guimarães
  • Published 2012
  • Medicine
  • Current pharmaceutical design
  • Δ(9)-tetrahydrocannabinol (Δ(9)-THC) is the main compound of the Cannabis Sativa responsible for most of the effects of the plant. Another major constituent is cannabidiol (CBD), formerly regarded to be devoid of pharmacological activity. However, laboratory rodents and human studies have shown that this cannabinoid is able to prevent psychotic-like symptoms induced by high doses of Δ(9)- THC. Subsequent studies have demonstrated that CBD has antipsychotic effects as observed using animal… CONTINUE READING
    143 Citations
    A systematic review of the antipsychotic properties of cannabidiol in humans
    • 150
    • PDF
    Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders
    • 224
    • PDF
    Could cannabidiol be used as an alternative to antipsychotics?
    • Marc Fakhoury
    • Psychology, Medicine
    • Journal of psychiatric research
    • 2016
    • 20
    • PDF
    Cannabidiol as a potential treatment for psychosis
    • 15
    • PDF
    Cannabinoids in the Treatment of Epilepsy: Hard Evidence at Last?
    • E. Perucca
    • Medicine
    • Journal of epilepsy research
    • 2017
    • 99
    • PDF
    Preclinical and Clinical Evidence Supporting Use of Cannabidiol in Psychiatry
    • 3
    • PDF


    Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.
    • 343
    • PDF
    Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action.
    • A. W. Zuardi
    • Psychology, Medicine
    • Revista brasileira de psiquiatria
    • 2008
    • 294
    • PDF
    [Therapeutical use of the cannabinoids in psychiatry].
    • 59
    • PDF
    Safety and side effects of cannabidiol, a Cannabis sativa constituent.
    • 266
    • PDF
    Effect of cannabidiol in a MK-801-rodent model of aspects of Schizophrenia
    • 63
    Cannabidiol monotherapy for treatment-resistant schizophrenia
    • 144
    Effects of cannabidiol in animal models predictive of antipsychotic activity
    • 150
    Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
    • 565
    • Highly Influential
    • PDF
    The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning.
    • 242